Aptose Biosciences logo
Aptose Biosciences APTO
report update icon

Quarterly report 2026-Q1
added 05-13-2026

Aptose Biosciences Financial Statements 2025-2011 | APTO

Annual Financial Statements Aptose Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 2.32 M 360 K 9.84 M 89.1 M 337 M 347 M 68.5 M 67.6 M - 35 M 29.4 M 8.87 M 9.32 M 9.21 M

Shares

2.45 M 699 K 225 K 6.15 M 89.1 M 81.8 M 50.2 M 33.4 M 22.3 M - 11.9 M 5.22 M 3.52 M 1.69 M 1.1 M

Historical Prices

- 3.32 1.6 1.6 1.2 3.96 8.01 1.76 2.79 1.14 2.77 4.97 8.64 2.76 2.4

Net Income

-25.5 M -25.4 M -51.2 M -10 M -65.4 M -55.2 M -26.3 M -28.9 M -11.7 M -13.9 M -10.5 M -9.73 M -5.4 M -4.48 M -5.16 M

EBITDA

22 K 32 K 88 K 120 K 150 K -55.2 M -26.7 M -29 M -11.7 M -13.7 M -11.3 M -8.77 M -5.36 M -4.42 M -5.04 M

Operating Expenses

24.7 M 26.3 M 52.4 M 42.6 M 65.4 M 55.8 M 26.9 M - - - - - - - -

General and Administrative Expenses

13.4 M 11.2 M 15.6 M 14.5 M 19.5 M 26.3 M 9.9 M 10.3 M 5.5 M 6.13 M 7.05 M 6.07 M 2.2 M 2.14 M 2.69 M

All numbers in USD currency

Quarterly Income Statement Aptose Biosciences

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.55 M 2.55 M 2.55 M 2.13 M 2.01 M 614 K 558 K 438 K 7.94 M 6.5 M 6.23 M 6.17 M 6.16 M 6.15 M 6.15 M 92.2 M 92.2 M 88.9 M 88.9 M 88.9 M 88.9 M 85.9 M 76.3 M 76.2 M 76.1 M 55.5 M 46.5 M 39.8 M 38.2 M 34.6 M 34 M 29 M 27.5 M 24.1 M 21.3 M 17.4 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-7.63 M -5.12 M -7.04 M -5.54 M - -6.95 M -7.25 M -9.64 M - -11.4 M -14.1 M -13.7 M - -9.78 M -10.6 M -11.5 M -24.3 M -11.3 M -13.5 M -16.2 M -14.7 M -13.2 M -15.8 M -11.5 M -7.71 M -6.84 M -6.22 M -5.51 M -6.26 M -5.53 M -10.3 M -6.81 M -3.27 M -2.64 M -2.44 M -3.29 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-19 K -212 K -110 K -84 K - 12 K 93 K 121 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

2 K - - 3 K - - 8 K 16 K - 20 K 22 K 28 K - 30 K 30 K 32 K - 36 K 35 K 35 K - 37 K 37 K 41 K - 33 K 53 K 29 K - 29 K 19 K 16 K - 20 K 23 K 23 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

7.18 M 4.91 M 6.92 M 5.46 M - 6.96 M 7.34 M 9.76 M - 11.7 M 14.5 M 14.1 M - 10 M 10.7 M 11.5 M - 11.4 M 13.5 M 16.3 M - 13.3 M 15.9 M 11.8 M - 7.03 M 6.35 M 5.6 M - 5.61 M 10.3 M 6.84 M - 2.71 M 2.48 M 3.32 M - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

3.56 M 2.71 M 3.62 M 3.1 M - 2.26 M 2.93 M 3.32 M - 3.42 M 3.87 M 5.28 M - 3.45 M 3.33 M 4.11 M - 3.64 M 3.66 M 8.02 M - 5.78 M 9.02 M 5.9 M - 2.28 M 2.86 M 2.26 M - 2.02 M 2.51 M 3.7 M - 1.32 M 1.39 M 1.59 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aptose Biosciences APTO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aptose Biosciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 37.19 0.24 % $ 2.95 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 9.56 1.53 % $ 1.53 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 2.9 0.17 % $ 123 M usaUSA
Xencor Xencor
XNCR
$ 24.95 0.86 % $ 1.85 B usaUSA
22nd Century Group 22nd Century Group
XXII
$ 0.84 4.78 % $ 155 K usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 26.34 1.58 % $ 28.9 B chinaChina
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 2.77 2.03 % $ 199 M usaUSA
Zoetis Zoetis
ZTS
$ 69.83 0.07 % $ 31 B usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Mersana Therapeutics Mersana Therapeutics
MRSN
- - $ 3.56 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Morphic Holding Morphic Holding
MORF
- - $ 2.42 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain